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Tumors harboring both glandular and squamous differen-tiation form a rare subset of non–small cell lung carcino-ma known as adenosquamous carcinoma (ASC). Fewstudies have reported on series of ASCs, but all have
emphasized the aggressive behavior of these tumors.1,2 ASCs are
associated with a poor prognosis, despite relatively good differen-
tiation and mostly peripheral location, because of a high rate of
early metastatic spreading. Patients with ASC have been reported
to have a poorer prognosis than that of patients with either adeno-
carcinomas or squamous cell carcinomas, even in stages I or II.1,3
The aim of this study was to correlate the pathologic findings with
prognosis and to generate a reflection on the management of this
type of lung cancer.
Patients and Methods
From 1984 through 1999, 69 patients underwent surgical resection
for ASC of the lung. Mediastinoscopy was not routinely used pre-
operatively, but it was used in patients with mediastinal lymph
nodes of more than 1 cm on computed tomographic scan to rule
out N3 disease. Specimens from each of these patients were
reviewed critically by one of us (J.B.) and classified as ASC
according to the new histologic classification of lung and pleural
tumors.4 There were 50 men and 19 women. Mean age was 59 ±
10 years (range 35-83 years). Twenty-three (33%) patients were in
pathologic stage I, 17 (25%) in stage II, 23 (33%) in stage IIIA, 1
in stage IIIB, and 4 (6%) patients in stage IV.5 In 1 patient who
underwent wedge resection without nodal dissection, the disease
was not staged. The tumor was classified as central when located
in a main or segmental bronchus (25%) and as peripheral when
located distally in areas in which bronchi or bronchioles could not
be seen macroscopically (75%). Diameter of the resected ASCs
was 5.1 ± 2.9 cm (range 1.3-14 cm). The operative procedure con-
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sisted in pneumonectomy in 31 (45%) patients, lobectomy in 31
(45%), bilobectomy in 3 (4%), segmentectomy in 1 (1.5%), wedge
resection in 2 (3%), and exploratory thoracotomy for biopsy in 1
(1.5%) patient. Eighty-four percent of patients had complete tumor
resection associated with radical lymph node dissection.
Prognosis was analyzed according to tumor location, complete-
ness of resection, tumor differentiation, N involvement (N0, N1,
and N2), pleural invasion (P0: tumor with no pleural involvement;
P1: tumor that extends beyond the elastic layer of the visceral pleu-
ra but not on the pleural surface; P2: tumor that extends to the pleu-
ral surface but does not involve the parietal pleura; P3: tumor
involving the parietal pleura),6 and size of the tumor. For further
evaluation of the prognosis and comparison with other histologic
subtypes, the completely resected ASCs (n = 58) were compared
with the completely resected squamous cell carcinomas (n = 906)
and adenocarcinomas (n = 499) observed during the same period.
Survival curves of each subgroup were drawn by means of the
Kaplan-Meier method, and the statistical analysis was carried out
by means of the log-rank test. Prognostic factors were analyzed by
the Cox proportional hazards model.
TABLE 1. Clinicopathologic correlation in 52 patients with
completely resected ASC and radical lymph node dissec-
tion (not including in-hospital mortality and patients lost to
follow-up)
Five-year Median
n survival (%) (mo) P value
Proximal tumor 5 60 80 .01
Peripheral tumor 47 12 21
Differentiated 29 52 44 .03
Poorly differentiated 23 23 20
N0 27 47 42 .17
N1 + N2 25 30.8 19
P0 20 48.9 32 .005
P1-2 24 39.6 22
P3 8 0 10
≤3 cm* 17 75.1 100 .0005
>3 ≤ 5 cm 20 29.3 24
>5 cm 15 8.3 9
TNM stage I† 16 64.3 38.5 .027
TNM stage II 17 28.5 20.2
TNM stage III 19 15.4 13.8
*Tumor size ≤3 cm was compared with >3 ≤ 5 cm and >5 cm. 
†TNM stage I was compared with TNM stage II and stage III. P was not
significant when comparing stage II versus stage III.
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Discussion
This study confirms the aggressive biologic behavior of ASC, as
already pointed out by others.1,2 Our results reemphasize the fact
that ASC is a single, significant, and independent factor associated
with a poor prognosis.3 Moreover, our data show that the pejora-
tive characteristics of ASC are its peripheral location and its
propensity to invade the visceral pleura. Because such characteris-
tics may allow tumor cells to exfoliate within the pleural cavity, we
postulate that exfoliated tumor cells may be absorbed by the pleu-
ral lymphatics. So doing, those cells may reach the bloodstream,
contributing to cancer dissemination. Further studies are needed to
confirm our results. Should our hypothesis be verified, a more
aggressive approach including radical lymph node dissection and
adjuvant chemotherapy with or without radiation therapy might be
considered in all patients with ASC, whatever the stage.
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Results
In-hospital mortality was 3%. Pathologic examination revealed
differentiated ASCs in 39 patients and moderately or poorly dif-
ferentiated ASCs in 30 patients. ASC was intrapulmonary in 36%
of patients (P0) and had invaded the visceral pleura in 42% (P1-2)
and the parietal pleura in 22% (P3). Lymph node metastases were
found in 36 of 68 patients (53%): 32 (47%) patients had N0 dis-
ease, 13 (19%) had N1 disease, and 23 (34%) had N2 disease.
Thirty-one (45%) patients had adjuvant radiation therapy and 8
(12%) patients had adjuvant chemotherapy.
Five patients were lost to follow-up. Among the 64 remaining
patients, follow-up ranged from 0.5 to 118 months (mean 23.5
months). Global 5-year survival was 33.1% (median 20.3 months).
Five-year survival was 36.7% (median 25 months) in patients with
complete resection and 11.1% (median 15 months) in patients with
incomplete resection, a difference approaching statistical signifi-
cance (P = .07). The most significant pathologic characteristics
were cell type differentiation, tumor size, location of the tumor,
and visceral pleura invasion (P1-2) (Table 1). P1-2 involvement was
the most common factor associated with size of the tumor (P1-2,
86% in tumors ≥5 cm) and location of the tumor (P1-2, 67% among
peripheral tumors).
When comparing squamous cell carcinomas and adenocarcino-
mas to ASCs, we found P1-2 disease to be more frequent among
ASCs: squamous cell carcinomas P1-2, 13.5%; adenocarcinomas
P1-2, 25.5%; ASCs P1-2, 42% (P = .01). Five-year survival was also
significantly different among the 3 histologic subtypes of
non–small cell lung carcinoma, whatever the N involvement: squa-
mous cell carcinoma, 47.2% (median 51 months); adenocarcino-
ma, 43.3% (median 42 months); and ASC, 34.9% (median 26
months) (P = .02). Multivariate analysis indicated that ASC loca-
tion and pleural invasion were factors associated with a poor prog-
nosis (P = .01 and P = .06, respectively).
